US4522811A
(en)
|
1982-07-08 |
1985-06-11 |
Syntex (U.S.A.) Inc. |
Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
|
US5593992A
(en)
|
1993-07-16 |
1997-01-14 |
Smithkline Beecham Corporation |
Compounds
|
US5670527A
(en)
|
1993-07-16 |
1997-09-23 |
Smithkline Beecham Corporation |
Pyridyl imidazole compounds and compositions
|
US5658903A
(en)
|
1995-06-07 |
1997-08-19 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6369068B1
(en)
|
1995-06-07 |
2002-04-09 |
Smithkline Beecham Corporation |
Amino substituted pyrimidine containing compounds
|
AP9700912A0
(en)
|
1996-01-11 |
1997-01-31 |
Smithkline Beecham Corp |
Novel cycloalkyl substituted imidazoles
|
JP2001508395A
(ja)
|
1996-01-11 |
2001-06-26 |
スミスクライン・ビーチャム・コーポレイション |
新規シクロアルキル置換イミダゾール
|
ZA97175B
(en)
|
1996-01-11 |
1997-11-04 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds.
|
US6372741B1
(en)
|
1996-03-08 |
2002-04-16 |
Smithkline Beecham Corporation |
Use of CSAID™ compounds as inhibitors of angiogenesis
|
JP2000510327A
(ja)
|
1996-03-12 |
2000-08-15 |
スミスクライン・ビーチャム・コーポレイション |
医薬的に活性な化合物の同定方法
|
US6096748A
(en)
|
1996-03-13 |
2000-08-01 |
Smithkline Beecham Corporation |
Pyrimidine compounds useful in treating cytokine mediated diseases
|
JP2000507558A
(ja)
|
1996-03-25 |
2000-06-20 |
スミスクライン・ビーチャム・コーポレイション |
Cns損傷についての新規な治療
|
US6235760B1
(en)
|
1996-03-25 |
2001-05-22 |
Smithkline Beecham Corporation |
Treatment for CNS injuries
|
WO1998007425A1
(en)
|
1996-08-21 |
1998-02-26 |
Smithkline Beecham Corporation |
Imidazole compounds, compositions and use
|
US6096753A
(en)
|
1996-12-05 |
2000-08-01 |
Amgen Inc. |
Substituted pyrimidinone and pyridone compounds and methods of use
|
US6147080A
(en)
|
1996-12-18 |
2000-11-14 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of p38
|
UA65572C2
(en)
|
1997-04-24 |
2004-04-15 |
Ortho Mcneil Pharm Inc |
Substituted imidazoles, intermediate compounds for the preparation thereof, a method for the preparation of substituted imidazoles and a method for the treatment of inflammatory diseases
|
US6514977B1
(en)
|
1997-05-22 |
2003-02-04 |
G.D. Searle & Company |
Substituted pyrazoles as p38 kinase inhibitors
|
JP2002504909A
(ja)
|
1997-06-13 |
2002-02-12 |
スミスクライン・ビーチャム・コーポレイション |
新規な置換ピラゾールおよびピラゾリン化合物
|
EP0994870A4
(en)
|
1997-06-19 |
2002-10-23 |
Smithkline Beecham |
NEW IMIDAZOLE COMPOUNDS SUBSTITUTED BY AN ARYLOXYREST
|
US6093742A
(en)
|
1997-06-27 |
2000-07-25 |
Vertex Pharmaceuticals, Inc. |
Inhibitors of p38
|
AR016294A1
(es)
|
1997-07-02 |
2001-07-04 |
Smithkline Beecham Corp |
Compuesto de imidazol sustituido, composicion farmaceutica que la contiene, su uso en la fabricacion de un medicamento y procedimiento para supreparacion
|
TW517055B
(en)
|
1997-07-02 |
2003-01-11 |
Smithkline Beecham Corp |
Novel substituted imidazole compounds
|
GB9721437D0
(en)
|
1997-10-10 |
1997-12-10 |
Glaxo Group Ltd |
Heteroaromatic compounds and their use in medicine
|
PL340412A1
(en)
|
1997-10-20 |
2001-01-29 |
Hoffmann La Roche |
Bicyclic kinase inhibitors
|
JP2002515891A
(ja)
|
1997-12-19 |
2002-05-28 |
スミスクライン・ビーチャム・コーポレイション |
新規なピペリジン含有化合物
|
US6162613A
(en)
|
1998-02-18 |
2000-12-19 |
Vertex Pharmaceuticals, Inc. |
Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
|
NZ507558A
(en)
|
1998-05-05 |
2003-08-29 |
F |
Pyrazole derivatives as P-38 map kinase inhibitors
|
US6316466B1
(en)
|
1998-05-05 |
2001-11-13 |
Syntex (U.S.A.) Llc |
Pyrazole derivatives P-38 MAP kinase inhibitors
|
MY132496A
(en)
|
1998-05-11 |
2007-10-31 |
Vertex Pharma |
Inhibitors of p38
|
US6867209B1
(en)
|
1998-05-22 |
2005-03-15 |
Scios, Inc. |
Indole-type derivatives as inhibitors of p38 kinase
|
US6589954B1
(en)
|
1998-05-22 |
2003-07-08 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
US6340685B1
(en)
|
1998-05-22 |
2002-01-22 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
WO1999061426A1
(en)
|
1998-05-22 |
1999-12-02 |
Scios Inc. |
Heterocyclic compounds and methods to treat cardiac failure and other disorders
|
TR200003472T2
(tr)
|
1998-05-22 |
2001-09-21 |
Smithkline Beecham Corporation |
Yeni 2-alkil ikameli imidazol bileşikler
|
US6448257B1
(en)
|
1998-05-22 |
2002-09-10 |
Scios, Inc. |
Compounds and methods to treat cardiac failure and other disorders
|
JP2002517486A
(ja)
|
1998-06-12 |
2002-06-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
p38のインヒビター
|
EP1112070B1
(en)
|
1998-08-20 |
2004-05-12 |
Smithkline Beecham Corporation |
Novel substituted triazole compounds
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
JP2002526482A
(ja)
|
1998-09-18 |
2002-08-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
p38のインヒビター
|
CA2346665A1
(en)
|
1998-10-07 |
2000-04-13 |
Smithkline Beecham Corporation |
Novel treatment for stroke management
|
AU1909200A
(en)
|
1998-11-04 |
2000-05-22 |
Smithkline Beecham Corporation |
Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
|
UA73492C2
(en)
|
1999-01-19 |
2005-08-15 |
|
Aromatic heterocyclic compounds as antiinflammatory agents
|
US7101899B1
(en)
|
1999-04-23 |
2006-09-05 |
Takeda Pharmaceutical Company Limited |
5-pyridyl-1,3-azole compounds, process for producing the same and use thereof
|
BR0011274A
(pt)
|
1999-05-21 |
2002-02-26 |
Scios Inc |
Derivados tipo indol como inibidores de p38 quinase
|
DE60024830T2
(de)
|
1999-07-09 |
2006-06-14 |
Boehringer Ingelheim Pharma |
Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen
|
US6541477B2
(en)
|
1999-08-27 |
2003-04-01 |
Scios, Inc. |
Inhibitors of p38-a kinase
|
WO2001019322A2
(en)
|
1999-09-17 |
2001-03-22 |
Smithkline Beecham Corporation |
Use of csaids in rhinovirus infection
|
ATE353329T1
(de)
|
1999-10-21 |
2007-02-15 |
Hoffmann La Roche |
Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen
|
CN1156477C
(zh)
|
1999-10-21 |
2004-07-07 |
霍夫曼-拉罗奇有限公司 |
作为p38蛋白激酶的抑制剂的烷基氨基-取代的双环氮杂环类化合物
|
AU1781601A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
|
DE60020595T2
(de)
|
1999-11-23 |
2006-03-16 |
Smithkline Beecham Corp. |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren
|
AU1626001A
(en)
|
1999-11-23 |
2001-06-04 |
Smithkline Beecham Corporation |
3,4-dihydro-(1h)-quinazolin-2-ones and their use as csbp/p38 kinase inhibitors
|
ATE305787T1
(de)
|
1999-11-23 |
2005-10-15 |
Smithkline Beecham Corp |
3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p39-kinase-inhibitoren
|
WO2001047921A1
(en)
|
1999-12-28 |
2001-07-05 |
Pharmacopeia, Inc. |
Pyrimidine and triazine kinase inhibitors
|
US6906067B2
(en)
|
1999-12-28 |
2005-06-14 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of TNF-α expression
|
WO2001064676A2
(en)
|
2000-02-28 |
2001-09-07 |
Scios, Inc. |
INHIBITORS OF p38-α KINASE
|
MY141144A
(en)
|
2000-03-02 |
2010-03-15 |
Smithkline Beecham Corp |
1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
|
JP2004504360A
(ja)
|
2000-07-24 |
2004-02-12 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
1−(5−tert−ブチル−2−P−トリル−2H−ピラゾール−3−イル)−3−[4−(2−モルホリン−4−イル−エトキシ)−ナフタレン−1−イル]−ウレアの改良された経口製剤
|
PE20020506A1
(es)
|
2000-08-22 |
2002-07-09 |
Glaxo Group Ltd |
Derivados de pirazol fusionados como inhibidores de la proteina cinasa
|
AU9378401A
(en)
|
2000-08-31 |
2002-03-13 |
Hoffmann La Roche |
7-oxo pyridopyrimidines as inhibitors of a cellular proliferation
|
MXPA03001733A
(es)
|
2000-08-31 |
2003-05-27 |
Hoffmann La Roche |
7-oxo-piridopirimidinas.
|
EP1337250A2
(en)
|
2000-10-19 |
2003-08-27 |
SmithKline Beecham Corporation |
Use of p38 inhibitors for the treatment of smoke inhalation
|
AU2002248269A1
(en)
|
2000-10-19 |
2002-08-12 |
Smithkline Beecham Corporation |
Use of p38 inhibitors for the treatment of inflammation-enhanced cough
|
CZ20031125A3
(cs)
|
2000-10-23 |
2003-10-15 |
Smithkline Beecham Corporation |
Nové sloučeniny
|
CA2429628A1
(en)
|
2000-11-17 |
2002-05-23 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
US6821966B2
(en)
|
2000-11-20 |
2004-11-23 |
Scios, Inc. |
Inhibitors of p38 kinase
|
JP2004533989A
(ja)
|
2000-11-20 |
2004-11-11 |
サイオス インコーポレイテッド |
p38キナーゼのピペリジン/ピペラジン型阻害剤
|
CA2429382A1
(en)
|
2000-11-20 |
2002-06-06 |
Scios Inc. |
Indole-type inhibitors of p38 kinase
|
US20020165286A1
(en)
|
2000-12-08 |
2002-11-07 |
Hanne Hedeman |
Dermal anti-inflammatory composition
|
CA2431904A1
(en)
|
2000-12-20 |
2002-08-01 |
Merck & Co., Inc. |
(halo-benzo carbonyl)heterocyclo fused phenyl p38 kinase inhibiting agents
|
HU229604B1
(en)
|
2001-02-12 |
2014-02-28 |
Hoffmann La Roche |
6-substituted pyrido-pyrimidines, process for their preparation and pharmaceutical compositions containing them
|
JP4302986B2
(ja)
|
2001-02-28 |
2009-07-29 |
テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション |
細胞及び組織をα,β不飽和アリールスルホンにより電離放射線から防護する方法
|
MXPA03008142A
(es)
|
2001-03-09 |
2003-12-12 |
Pfizer Prod Inc |
Nuevos compuestos antiinflamatorios de bencimidazol.
|
ATE323701T1
(de)
|
2001-03-09 |
2006-05-15 |
Pfizer Prod Inc |
Triazolopyridine als entzündungshemmende mittel
|
WO2002076954A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076985A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
AU2002303145A1
(en)
|
2001-03-23 |
2002-10-08 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076984A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
WO2002076463A1
(en)
|
2001-03-23 |
2002-10-03 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
DE60205974T2
(de)
|
2001-04-04 |
2006-06-29 |
Pfizer Products Inc., Groton |
Neue Benzotriazole mit entzündungshemmender Wirkung
|
CN1247258C
(zh)
|
2001-04-24 |
2006-03-29 |
默克专利有限公司 |
使用抗血管生成剂和TNFα的联合疗法
|
WO2002090360A1
(en)
|
2001-05-10 |
2002-11-14 |
Smithkline Beecham Corporation |
Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
|
MXPA03010269A
(es)
|
2001-05-11 |
2004-05-05 |
Vertex Pharma |
Derivados de 2,5-disubstituida piridina, pirimidina, piridazina y 1,2,4-triazina para usarse como inhibidores de p38.
|
CN1951939A
(zh)
|
2001-05-24 |
2007-04-25 |
伊莱利利公司 |
作为药物的新的吡唑衍生物
|
EP2036891A3
(en)
|
2001-06-11 |
2009-03-25 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline inhibitors of P38
|
CA2450555A1
(en)
|
2001-06-25 |
2003-01-03 |
Merck & Co., Inc. |
(pyrimidyl)(phenyl)substituted fused heteroaryl p38 inhibiting and pkg kinase inhibiting compounds
|
CA2451128A1
(en)
|
2001-06-26 |
2003-01-09 |
Bristol-Myers Squibb Company |
N-heterocyclic inhibitors of tnf-alpha expression
|
DE60219793T2
(de)
|
2001-07-11 |
2008-01-24 |
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield |
Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen
|
CA2454913A1
(en)
|
2001-08-20 |
2003-02-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2h-pryrazol-3-yl)-3-¬4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl|-urea and a cyclodextrin
|
AU2002331179B2
(en)
|
2001-08-30 |
2008-04-17 |
F. Hoffmann-La Roche Ag |
Aminopyrrole compounds as antiinflammatory agents
|
AU2002330031B2
(en)
|
2001-09-21 |
2007-07-05 |
Merck & Co., Inc. |
Androstanes as androgen receptor modulators
|
US7205275B2
(en)
|
2001-10-11 |
2007-04-17 |
Amgen Inc. |
Methods of treatment using specific binding agents of human angiopoietin-2
|
AU2002329570A1
(en)
|
2001-10-12 |
2003-01-30 |
Pfizer Products Inc. |
Method of monitoring neuroprotective treatment
|
GB0124936D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124931D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124939D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124928D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124933D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124932D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
GB0124938D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
CA2465499A1
(en)
|
2001-11-08 |
2003-05-15 |
Merck & Co., Inc. |
Compositions and methods for treating osteoporosis
|
US20040009990A1
(en)
|
2001-11-09 |
2004-01-15 |
Higgins Linda S. |
Method to treat cystic fibrosis
|
EP1461758A4
(en)
|
2001-12-05 |
2005-10-05 |
Vertex Pharma |
CRYSTAL STRUCTURE OF AN MITOGENIC ACTIVATED PROTEIN, KINASE-ACTIVATED PROTEIN, KINASE-2 AND BINDING POCKETS THEREFOR
|
WO2003049742A1
(en)
|
2001-12-11 |
2003-06-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Method for administering birb 796 bs
|
AU2003206382B2
(en)
|
2002-01-03 |
2008-01-24 |
Smithkline Beecham Corporation |
Novel pharmaceutical dosage forms and method for producing same
|
EP1467739A4
(en)
|
2002-01-15 |
2008-01-09 |
Merck & Co Inc |
17-HYDROXY-4-AZA-ANDROSTAN-3-ONE AS ANDROGEN RECEPTOR MODULATORS
|
DE10203749A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203741A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE10203753A1
(de)
|
2002-01-31 |
2003-08-14 |
Boehringer Ingelheim Pharma |
Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
US20040023961A1
(en)
|
2002-02-11 |
2004-02-05 |
Bayer Corporation |
Aryl ureas with raf kinase and angiogenisis inhibiting activity
|
MXPA04007838A
(es)
*
|
2002-02-12 |
2004-10-15 |
Smithkline Beecham Corp |
Derivados de nicotamida utiles como inhibidores p38.
|
BR0308232A
(pt)
|
2002-03-07 |
2004-12-28 |
Hoffmann La Roche |
Inibidores de cinase p38 de piridina e pirimidina bicìclicas
|
BR0308355A
(pt)
|
2002-03-13 |
2005-01-25 |
Merck & Co Inc |
Composto ou um sal farmaceuticamente aceitável ou um seu enanciÈmero, métodos para modular uma função mediada pelo receptor de androgênio em um mamìfero em necessidade de tal modulação, para ativar a função do receptor de androgênio em um mamìfero em necessidade de tal ativação, para tratar uma condição em um mamìfero, e para tratar osteoporose em um mamìfero em sua necessidade, composição farmacêutica, métodos para aumentar a densidade mineral óssea em um mamìfero em necessidade disto, para reduzir o risco de fraturas vertebrais ou não vertebrais em um mamìfero em necessidade disto, e para produzir um marcador de modificação óssea em um mamìfero em necessidade disto, processo para produzir uma composição farmacêutica, e, método para tratar ou prevenir uma condição artrìtica em um mamìfero em necessidade disto
|
US7101883B2
(en)
|
2002-03-18 |
2006-09-05 |
Bristol-Myers Squibb Company |
Uracil derivatives as inhibitors of TNF-α converting enzyme (TACE) and matrix metalloproteinases
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
EP1492790A1
(en)
|
2002-04-03 |
2005-01-05 |
F. Hoffmann-La Roche Ag |
Imidazo fused compounds
|
BR0309009A
(pt)
|
2002-04-05 |
2005-03-22 |
Boehringer Ingelheim Pharma |
Método para o tratamento de hipersecreção de muco
|
US20030225089A1
(en)
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
DE10216339A1
(de)
|
2002-04-13 |
2003-10-23 |
Boehringer Ingelheim Pharma |
Neue Ester hydroxy-substituierter Stickstoffheterocyclen, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
WO2003087394A1
(en)
|
2002-04-15 |
2003-10-23 |
Glaxo Group Limited |
A method of identifying a modudator for a serine/theronine kinase
|
PL373339A1
(en)
|
2002-04-19 |
2005-08-22 |
Smithkline Beecham Corporation |
Novel compounds
|
WO2003091229A1
(en)
|
2002-04-23 |
2003-11-06 |
Bristol-Myers Squibb Company |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
EP2289894A3
(en)
|
2002-04-23 |
2011-07-20 |
Bristol-Myers Squibb Company |
Pyrrolo-triazine compounds useful as kinase inhibitors
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
GB0209891D0
(en)
|
2002-04-30 |
2002-06-05 |
Glaxo Group Ltd |
Novel compounds
|
JP4516839B2
(ja)
|
2002-04-30 |
2010-08-04 |
メルク・シャープ・エンド・ドーム・コーポレイション |
アンドロゲン受容体修飾因子としての4−アザステロイド誘導体
|
AU2003229305A1
(en)
|
2002-05-17 |
2003-12-02 |
Scios, Inc. |
TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
AU2003239508A1
(en)
|
2002-05-21 |
2003-12-12 |
Bristol-Myers Squibb Company |
Indole compounds useful as impdh inhibitors
|
WO2003103590A2
(en)
|
2002-06-11 |
2003-12-18 |
Merck & Co., Inc. |
(halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
|
WO2004004725A2
(en)
|
2002-07-09 |
2004-01-15 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
CA2494367A1
(en)
|
2002-07-25 |
2004-02-05 |
Scios Inc. |
Methods for improvement of lung function using tgf-.beta. inhibitors
|
GB0217757D0
(en)
|
2002-07-31 |
2002-09-11 |
Glaxo Group Ltd |
Novel compounds
|
DE60316581T2
(de)
|
2002-08-06 |
2008-07-03 |
F. Hoffmann-La Roche Ag |
6-alkoxypyridopyrimidine als inhibitoren der p-38-map-kinase
|
JP2006504667A
(ja)
|
2002-08-08 |
2006-02-09 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
炎症過程に関与するサイトカインの抑制剤としてのフッ素化フェニル−ナフタレニル−尿素化合物
|
EP1554272B1
(en)
|
2002-08-09 |
2006-10-25 |
Eli Lilly And Company |
Benzimidazoles and benzothiazoles as inhibitors of map kinase
|
US20040110755A1
(en)
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
WO2004016267A1
(en)
|
2002-08-14 |
2004-02-26 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Anticoagulant and fibrinolytic therapy using p38 map kinase inhibitors
|
US7268139B2
(en)
|
2002-08-29 |
2007-09-11 |
Scios, Inc. |
Methods of promoting osteogenesis
|
US20040092547A1
(en)
|
2002-08-30 |
2004-05-13 |
Pfizer Inc |
Alkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
PA8579601A1
(es)
|
2002-08-30 |
2004-05-07 |
Pfizer Prod Inc |
Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
|
US7005523B2
(en)
|
2002-08-30 |
2006-02-28 |
Pfizer Inc. |
Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines
|
US7012143B2
(en)
|
2002-08-30 |
2006-03-14 |
Dombroski Mark A |
Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
JP2006508914A
(ja)
|
2002-08-30 |
2006-03-16 |
ファイザー・プロダクツ・インク |
トリアゾロ−ピリジン製造のための新規な方法および中間体
|
US7037923B2
(en)
|
2002-08-30 |
2006-05-02 |
Pfizer, Inc. |
Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines
|
JP2006506346A
(ja)
|
2002-09-03 |
2006-02-23 |
サイオス インク. |
p38キナーゼ阻害剤としてのインドール系誘導体
|
AU2003268424A1
(en)
|
2002-09-05 |
2004-03-29 |
Scios Inc. |
Treatment of pain by inhibition of p38 map kinase
|
US20050288503A1
(en)
|
2002-09-06 |
2005-12-29 |
Adams Jerry L |
Novel compounds
|
US7115644B2
(en)
|
2002-09-13 |
2006-10-03 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic compounds
|
DE60315677T2
(de)
|
2002-09-17 |
2008-06-05 |
Eli Lilly And Co., Indianapolis |
Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
|
MXPA05003264A
(es)
|
2002-09-27 |
2005-10-18 |
Johnson & Johnson |
Pirroles 3,4-disustituidos y su uso en el tratamiento de enfermedades inflamatorias.
|
AU2003282920A1
(en)
|
2002-10-04 |
2004-05-04 |
Bristol-Myers Squibb Company |
Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
|
EP1560582A4
(en)
|
2002-10-09 |
2008-03-12 |
Scios Inc |
AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
|
US20050288299A1
(en)
|
2002-10-09 |
2005-12-29 |
Mavunkel Babu J |
Azaindole derivatives as inhibitors of p38 kinase
|
AU2003286757B2
(en)
|
2002-11-01 |
2009-06-04 |
Merck Sharp & Dohme Corp. |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
JP2006514624A
(ja)
|
2002-11-18 |
2006-05-11 |
エフ.ホフマン−ラ ロシュ アーゲー |
ジアジノピリミジン類
|
DE10255040A1
(de)
|
2002-11-26 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Carbaminsäureester mit anticholinerger Wirksamkeit
|
JP2006510654A
(ja)
|
2002-12-06 |
2006-03-30 |
サイオス・インコーポレーテツド |
糖尿病を処置する方法
|
US7105537B2
(en)
|
2003-01-28 |
2006-09-12 |
Bristol-Myers Squibb Company |
2-substituted cyclic amines as calcium sensing receptor modulators
|
MXPA05008183A
(es)
|
2003-02-05 |
2005-10-05 |
Bristol Myers Squibb Co |
Proceso para preparar pirrolotriazina como inhibidores de cinasa.
|
JP4675318B2
(ja)
|
2003-02-10 |
2011-04-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−アリールカルバミン酸エステルとハロ−ヘテロアリールとを反応させることによるn−ヘテロアリール−n−アリール−アミンの調製のためのプロセスおよび類似のプロセス
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
ES2264795T3
(es)
|
2003-02-14 |
2007-01-16 |
Pfizer Products Inc. |
Triazolo-piridinas como compuestos antiinflamatorios.
|
JP2006517976A
(ja)
|
2003-02-14 |
2006-08-03 |
スミスクライン・ビーチャム・コーポレイション |
新規化合物
|
RS51768B
(sr)
|
2003-02-27 |
2011-12-31 |
Palau Pharma S.A. |
Derivati pirazolpiridina
|
JP4617299B2
(ja)
|
2003-03-03 |
2011-01-19 |
アレイ バイオファーマ、インコーポレイテッド |
p38阻害剤及びその使用法
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7030112B2
(en)
|
2003-03-25 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
GB0308186D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308185D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
GB0308201D0
(en)
|
2003-04-09 |
2003-05-14 |
Smithkline Beecham Corp |
Novel compounds
|
JP2006523638A
(ja)
|
2003-04-16 |
2006-10-19 |
エフ.ホフマン−ラ ロシュ アーゲー |
キナゾリン化合物
|
RU2005135329A
(ru)
|
2003-04-16 |
2006-08-10 |
Ф.Хоффманн-Ля Рош Аг (Ch) |
Замещенные 7-азахиназолины
|
WO2004098528A2
(en)
|
2003-05-01 |
2004-11-18 |
Bristol-Myers Squibb Company |
Pyrazole-amine compounds useful as kinase inhibitors
|
GB0320244D0
(en)
|
2003-05-06 |
2003-10-01 |
Aventis Pharma Inc |
Pyrazoles as inhibitors of tumour necrosis factor
|
CN1784236A
(zh)
|
2003-05-07 |
2006-06-07 |
麦克公司 |
雄激素受体调节剂及其使用方法
|
CA2527334A1
(en)
|
2003-06-04 |
2004-12-16 |
Pfizer Inc. |
2-amino-pyridine derivatives as beta-2 adrenoreceptor agonists
|
TWI452035B
(zh)
|
2003-06-26 |
2014-09-11 |
Novartis Ag |
以5員雜環為主之p38激酶抑制劑
|
JP2007521293A
(ja)
|
2003-06-30 |
2007-08-02 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体
|
JP2007521292A
(ja)
|
2003-06-30 |
2007-08-02 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレータとしての17−アセトアミド−4−アザステロイド誘導体
|
WO2005009367A2
(en)
|
2003-07-17 |
2005-02-03 |
Ambit Biosciences Corporation |
Treatment of diseases with kinase inhibitors
|
US7153870B2
(en)
|
2003-07-25 |
2006-12-26 |
Pfizer Inc. |
Nicotinamide derivatives useful as PDE4 inhibitors
|
US20050020587A1
(en)
|
2003-07-25 |
2005-01-27 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
GB0317482D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
GB0317516D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as PDE4 inhibitors
|
GB0317484D0
(en)
|
2003-07-25 |
2003-08-27 |
Pfizer Ltd |
Nicotinamide derivatives useful as pde4 inhibitors
|
WO2005012875A2
(en)
|
2003-07-29 |
2005-02-10 |
Bristol-Myers Squibb Company |
Biomarkers of cyclin-dependent kinase modulation
|
GB0318814D0
(en)
|
2003-08-11 |
2003-09-10 |
Smithkline Beecham Corp |
Novel compounds
|
NL1026826C2
(nl)
|
2003-08-13 |
2007-01-04 |
Pharmacia Corp |
Gesubstitueerde pyridinonen.
|
CN1838958A
(zh)
|
2003-08-22 |
2006-09-27 |
贝林格尔·英格海姆药物公司 |
治疗慢性阻塞性肺病和肺动脉高血压的方法
|
US20050053600A1
(en)
|
2003-09-09 |
2005-03-10 |
Lane Thomas E. |
Methods for treating rheumatoid arthritis
|
CN1849120A
(zh)
|
2003-09-10 |
2006-10-18 |
默克公司 |
作为雄激素受体调节剂的17-杂环-4-氮杂甾类衍生物
|
AU2004270733B2
(en)
|
2003-09-11 |
2011-05-19 |
Itherx Pharma, Inc. |
Cytokine inhibitors
|
WO2005032551A1
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
WO2005032481A2
(en)
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
Quinazoline derivatives as medicaments
|
EP1675830A4
(en)
|
2003-09-30 |
2008-08-20 |
Scios Inc |
HETEROCYCLIC AMIDES AND SULFONAMIDES
|
US7419978B2
(en)
|
2003-10-22 |
2008-09-02 |
Bristol-Myers Squibb Company |
Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
|
DK1685131T3
(da)
|
2003-11-13 |
2007-07-09 |
Hoffmann La Roche |
Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner
|
EP1538201A1
(en)
|
2003-12-02 |
2005-06-08 |
F.Hoffmann-La Roche Ag |
Method for the recombinant production and purification of protein kinases
|
GB0329275D0
(en)
|
2003-12-18 |
2004-01-21 |
Merck Sharp & Dohme |
Therapeutic treatment
|
WO2005063715A1
(en)
|
2003-12-18 |
2005-07-14 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Polymorph of birb 796, a p38map kinase inhibitor
|
CA2550064A1
(en)
|
2003-12-18 |
2005-07-07 |
Pfizer Products Inc. |
Methods of treating acute inflammation in animals with p38 map kinase inhibitors
|
US20060058296A1
(en)
|
2003-12-24 |
2006-03-16 |
Scios, Inc. |
Treatment of osteolytic lesions associated with multiple myeloma by inhibition of p38 map kinase
|
MXPA06008157A
(es)
|
2003-12-24 |
2007-09-07 |
Johnson & Johnson |
Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
|
US20060079461A1
(en)
|
2003-12-24 |
2006-04-13 |
Scios, Inc. |
Treatment of multiple myeloma by inhibition of p38 MAP kinase
|
US20060052390A1
(en)
|
2003-12-24 |
2006-03-09 |
Scios, Inc. |
Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
|
GB0402143D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402138D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
US20070161677A1
(en)
|
2004-01-30 |
2007-07-12 |
Merck Patent Gmbh |
Bisarylurea derivatives
|
GB0402137D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
GB0402140D0
(en)
|
2004-01-30 |
2004-03-03 |
Smithkline Beecham Corp |
Novel compounds
|
TWI332003B
(en)
|
2004-01-30 |
2010-10-21 |
Lilly Co Eli |
Kinase inhibitors
|
US7863310B2
(en)
|
2004-02-03 |
2011-01-04 |
Eli Lilly And Company |
Kinase inhibitors
|
US7652146B2
(en)
|
2004-02-06 |
2010-01-26 |
Bristol-Myers Squibb Company |
Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
|
TWI338004B
(en)
|
2004-02-06 |
2011-03-01 |
Bristol Myers Squibb Co |
Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
|
JP2007523929A
(ja)
|
2004-02-26 |
2007-08-23 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
ベンズイミダゾリル誘導体
|
WO2005085248A1
(en)
|
2004-02-27 |
2005-09-15 |
F.Hoffmann-La Roche Ag |
Heteroaryl-fused pyrazolo derivatives
|
EP1747202A1
(en)
|
2004-02-27 |
2007-01-31 |
F.Hoffmann-La Roche Ag |
Indazole derivatives and pharmaceutical compositions containing them
|
EP1574501A1
(en)
|
2004-03-11 |
2005-09-14 |
Pfizer Limited |
Quinolinone derivatives, pharmaceutical compositions containing them and their use
|
CA2558439A1
(en)
|
2004-03-11 |
2005-10-06 |
Kythera Biopharmaceuticals, Inc. |
Compositions and methods for preventing and treating skin and hair conditions
|
EP1577292A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylaminoethanol derivatives as beta2 receptor agonists
|
EP1577291A1
(en)
|
2004-03-17 |
2005-09-21 |
Pfizer Limited |
Phenylethanolamine derivatives as beta-2 agonists
|
WO2005105091A1
(en)
|
2004-04-28 |
2005-11-10 |
Merck & Co., Inc. |
Fluorinated 4-azasteroids as androgen receptor modulators
|
CA2566677A1
(en)
|
2004-05-13 |
2005-11-24 |
Intermune, Inc. |
Combination therapy for treating hepatitis virus infection
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
DK1761520T3
(da)
|
2004-06-23 |
2008-10-27 |
Lilly Co Eli |
Kinaseinhibitorer
|
EP1609789A1
(en)
|
2004-06-23 |
2005-12-28 |
Eli Lilly And Company |
Ureido-pyrazole derivatives and their use as kinase inhibitors
|
US7253167B2
(en)
|
2004-06-30 |
2007-08-07 |
Bristol-Myers Squibb Company |
Tricyclic-heteroaryl compounds useful as kinase inhibitors
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
AP2326A
(en)
|
2004-08-12 |
2011-11-24 |
Pfizer |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
JP2008510811A
(ja)
|
2004-08-25 |
2008-04-10 |
メルク エンド カムパニー インコーポレーテッド |
アンドロゲン受容体モジュレーター
|
US20070054916A1
(en)
|
2004-10-01 |
2007-03-08 |
Amgen Inc. |
Aryl nitrogen-containing bicyclic compounds and methods of use
|
TW200628153A
(en)
|
2004-10-05 |
2006-08-16 |
Smithkline Beecham Corp |
Novel compounds
|
US8003657B2
(en)
|
2004-10-13 |
2011-08-23 |
Merck Patent Gmbh |
Heterocyclic substituted bisarylurea derivatives
|
US7354944B2
(en)
|
2004-10-18 |
2008-04-08 |
Amgen Inc. |
Thiadiazole compounds and methods of use
|
AU2005310238A1
(en)
|
2004-10-29 |
2006-06-08 |
Merck Sharp & Dohme Corp. |
N-(pyridin-3-yl)-2-phenylbutanamides as androgen receptor modulators
|
WO2006055302A2
(en)
|
2004-11-04 |
2006-05-26 |
Scios Inc. |
Method of treating myelodysplastic syndromes
|
WO2006048266A2
(en)
|
2004-11-04 |
2006-05-11 |
Roche Diagnostics Gmbh |
Gene expression profiling of leukemias with mll gene rearrangements
|
GB0425057D0
(en)
|
2004-11-12 |
2004-12-15 |
Pfizer Ltd |
L-tartrate salt of N-1-adamantyl-2-{3-[(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]eth yl}amino)propyl]phenyl}acetamide
|
WO2006051373A1
(en)
|
2004-11-12 |
2006-05-18 |
Pfizer Limited |
Compounds for the treatment of diseases
|
EP1814838A4
(en)
|
2004-11-16 |
2010-03-17 |
Merck Sharp & Dohme |
PRODRUGS FROM (2R) -2-PROPYLOCTANIC ACIDS FOR THE TREATMENT OF APOPLEXIA
|
US20080139614A1
(en)
|
2004-11-23 |
2008-06-12 |
Seabrook Guy R |
Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists
|
US20060111416A1
(en)
|
2004-11-24 |
2006-05-25 |
Lane Charlotte A L |
Octahydropyrrolo[3,4-C]pyrrole derivatives
|
US20070224662A1
(en)
|
2004-12-17 |
2007-09-27 |
Jun Luo |
Post-translational modification of proteins in cell-free expression systems
|
PE20061155A1
(es)
|
2004-12-24 |
2006-12-16 |
Boehringer Ingelheim Int |
Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
US20060154939A1
(en)
|
2004-12-24 |
2006-07-13 |
Boehringer Ingelheim International Gmbh |
Medicaments for the Treatment or Prevention of Fibrotic Diseases
|
CA2591912C
(en)
|
2004-12-28 |
2013-06-25 |
Aska Pharmaceutical Co., Ltd. |
Pyrimidinylisoxazole derivatives
|
US20060178388A1
(en)
|
2005-02-04 |
2006-08-10 |
Wrobleski Stephen T |
Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
|
WO2006089798A1
(en)
|
2005-02-28 |
2006-08-31 |
Merckle Gmbh |
2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
PE20100737A1
(es)
|
2005-03-25 |
2010-11-27 |
Glaxo Group Ltd |
Nuevos compuestos
|
PE20100741A1
(es)
|
2005-03-25 |
2010-11-25 |
Glaxo Group Ltd |
COMPUESTOS DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2(1H)-ONA COMO INHIBIDORES DE QUINASA p38
|
EP1868612A4
(en)
|
2005-03-25 |
2010-03-24 |
Glaxo Group Ltd |
NOVEL CONNECTIONS
|
US20060235020A1
(en)
|
2005-04-18 |
2006-10-19 |
Soojin Kim |
Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein
|
US20060264431A1
(en)
|
2005-05-11 |
2006-11-23 |
Array Biopharma Inc. |
P38 inhibitors and methods of use thereof
|
WO2006127678A2
(en)
|
2005-05-23 |
2006-11-30 |
Smithkline Beecham Corporation |
Inhibition of p38 mark for treatment of obesity
|
GB0512429D0
(en)
|
2005-06-17 |
2005-07-27 |
Smithkline Beecham Corp |
Novel compound
|
US20070032506A1
(en)
|
2005-07-02 |
2007-02-08 |
Peter Giannousis |
Crystalline forms of (2r-trans)-6-chloro-5[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n, 1-trimethyl-alpha-oxo-1h-indole-3-acetamide monohydrochloride
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
US20090088458A1
(en)
|
2005-08-02 |
2009-04-02 |
Meissner Robert S |
N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators
|
CN101273039A
(zh)
|
2005-08-12 |
2008-09-24 |
默克公司 |
可用作p38激酶抑制剂的杂二环化合物
|
WO2007024754A1
(en)
|
2005-08-22 |
2007-03-01 |
Amgen Inc. |
Bis-aryl urea compounds for the treatment of protein kinase-mediated diseaes
|
CN101243088B
(zh)
|
2005-08-25 |
2011-06-29 |
霍夫曼-拉罗奇有限公司 |
p38 MAP激酶抑制剂及使用它的方法
|
AU2006283935A1
(en)
|
2005-08-25 |
2007-03-01 |
F. Hoffmann-La Roche Ag |
Fused pyrazole as p38 MAP kinase inhibitors
|
BRPI0615272A2
(pt)
|
2005-08-25 |
2009-08-04 |
Hoffmann La Roche |
inibidores de p38 map kinase e métodos para uso dos mesmos
|
CA2620257A1
(en)
|
2005-08-25 |
2007-03-01 |
F. Hoffmann-La Roche Ag |
P38 map kinase inhibitors and methods for using the same
|
MX2008002385A
(es)
|
2005-08-25 |
2008-03-18 |
Hoffmann La Roche |
Inhibidores de proteinas cinasas activads por mitogenos p38 y metodos para utilizarlos.
|
TW200745034A
(en)
|
2005-09-01 |
2007-12-16 |
Astellas Pharma Inc |
New compounds
|
EP1928821B1
(en)
|
2005-09-21 |
2009-01-07 |
Pfizer Limited |
Carboxamide derivatives as muscarinic receptor antagonists
|
WO2007038444A2
(en)
|
2005-09-26 |
2007-04-05 |
Merck & Co., Inc. |
N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamides as androgen receptor modulators
|
WO2007045989A1
(en)
|
2005-10-20 |
2007-04-26 |
Pfizer Limited |
Pyridyl derivatives useful as h3 ligands
|
AR056582A1
(es)
|
2005-10-28 |
2007-10-10 |
Lilly Co Eli |
COMPUESTOS DE PIRAZOLIL UREA CON ACTIVIDAD INHIBITORIA DE CINASA P38 Y FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE
|
DOP2006000233A
(es)
|
2005-10-28 |
2007-06-15 |
Lilly Co Eli |
Inhibidores de cinasa
|
WO2007056016A2
(en)
|
2005-11-02 |
2007-05-18 |
Kemia, Inc. |
Bisamide cytokine inhibitors
|
JP2009514846A
(ja)
|
2005-11-04 |
2009-04-09 |
ファイザー・リミテッド |
テトラヒドロナフチリジン誘導体
|
AU2006313430B2
(en)
|
2005-11-08 |
2012-09-06 |
Ranbaxy Laboratories Limited |
Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
PE20070823A1
(es)
|
2005-11-15 |
2007-08-09 |
Glaxo Group Ltd |
Sal tosilato de 8-(2,6-difluorofenil)-4-(4-fluoro-2-metilfenil)-2-{[2-hidroxi-1-(hidroximetil)etil]amino}pirido[2,3-]pirimidin-7(8h)-ona
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
WO2007075896A2
(en)
|
2005-12-22 |
2007-07-05 |
Kemia, Inc. |
Heterocyclic cytokine inhibitors
|
CA2636077C
(en)
|
2006-01-18 |
2012-01-03 |
Amgen Inc. |
Thiazole compounds as protein kinase b (pkb) inhibitors
|
JP5131990B2
(ja)
|
2006-01-31 |
2013-01-30 |
アレイ バイオファーマ、インコーポレイテッド |
キナーゼ阻害剤およびその使用方法
|
EP1984363A1
(en)
|
2006-02-09 |
2008-10-29 |
Pfizer Limited |
Triazolopyridine compounds
|
JP2009526039A
(ja)
|
2006-02-10 |
2009-07-16 |
ファイザー・プロダクツ・インク |
ピリジノンピラゾール尿素およびピリミジノンピラゾール尿素誘導体
|
GB0603684D0
(en)
|
2006-02-23 |
2006-04-05 |
Novartis Ag |
Organic compounds
|
WO2007103468A2
(en)
|
2006-03-07 |
2007-09-13 |
Vertex Pharmaceuticals Incorporated |
Use of vx-702 for treating rheumatoid arthritis
|
KR20080107408A
(ko)
|
2006-03-07 |
2008-12-10 |
브리스톨-마이어스 스큅 컴퍼니 |
키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물
|
NZ570693A
(en)
|
2006-03-20 |
2011-02-25 |
Pfizer Ltd |
Amine derivatives
|
CN101454313A
(zh)
|
2006-03-29 |
2009-06-10 |
阿雷生物药品公司 |
P38抑制剂及其使用方法
|
EP2004631A1
(en)
|
2006-04-12 |
2008-12-24 |
Merck Patent GmbH |
N-oxides of heterocyclic substituted bisarylureas for treating kinase-mediated diseases
|
US7745449B2
(en)
|
2006-04-21 |
2010-06-29 |
Amgen Inc. |
Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
|
WO2007146712A2
(en)
|
2006-06-09 |
2007-12-21 |
Kemia, Inc. |
Therapy using cytokine inhibitors
|
JP2009542818A
(ja)
|
2006-06-16 |
2009-12-03 |
グラクソ グループ リミテッド |
新規化合物
|
EP2031965A4
(en)
|
2006-06-16 |
2010-06-30 |
Glaxo Group Ltd |
NEW COMPOUNDS
|
WO2007147103A2
(en)
|
2006-06-16 |
2007-12-21 |
Glaxo Group Limited |
Novel compounds
|
GB0612026D0
(en)
|
2006-06-16 |
2006-07-26 |
Smithkline Beecham Corp |
New use
|
WO2008001930A1
(fr)
|
2006-06-28 |
2008-01-03 |
Aska Pharmaceutical Co., Ltd. |
Dérivé de pyridylisoxazole
|
US20090192164A1
(en)
|
2006-06-28 |
2009-07-30 |
Aska Pharmaceutical Co., Ltd. |
Treating agent of inflammatory bowel disease
|
US7935709B2
(en)
|
2006-07-17 |
2011-05-03 |
Amgen Inc. |
2-quinazolinone compounds and methods of use
|
WO2008013823A2
(en)
|
2006-07-26 |
2008-01-31 |
Scios Inc. |
Co-crystals of (2r-trans)-6-chloro-5-[[4-[(4-fluorophenyl)methyl]-2,5-dimethyl-1-piperazinyl]carbonyl]-n,n,1-trimethyl-alpha-oxo-1h-indole-3-acetamide
|
US20090247624A1
(en)
|
2006-07-28 |
2009-10-01 |
Onconova Therapeutics Inc. |
Formulations of radioprotective alpha beta unsaturated aryl sulfones
|
PE20080906A1
(es)
|
2006-08-17 |
2008-07-05 |
Kemia Inc |
Derivados heteroarilo como inhibidores de citocina
|
WO2008024391A1
(en)
|
2006-08-22 |
2008-02-28 |
Scios Inc. |
Pharmaceutical formulations of an indole-type derivative and related methods of use
|
CA2665385A1
(en)
|
2006-10-04 |
2008-04-10 |
Pfizer Limited |
Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists
|
WO2008045393A2
(en)
|
2006-10-11 |
2008-04-17 |
Amgen Inc. |
Imidazo- and triazolo-pyridine compounds and methods of use therof
|
AU2007313295A1
(en)
|
2006-10-18 |
2008-04-24 |
Merck Sharp & Dohme Corp. |
2-hydroxy-2-phenyl/thiophenyl propionamides as androgen receptor modulators
|
WO2008049842A2
(en)
|
2006-10-26 |
2008-05-02 |
Boehringer Ingelheim International Gmbh |
Egfr kinase inhibitor combinations for the treatment of respiratory and gastrointestinal disorders
|
US7943617B2
(en)
|
2006-11-27 |
2011-05-17 |
Bristol-Myers Squibb Company |
Heterobicyclic compounds useful as kinase inhibitors
|
WO2008071665A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
A nicotinamide derivative useful as p38 kinase inhibitor
|
WO2008071664A1
(en)
|
2006-12-12 |
2008-06-19 |
Smithkline Beecham Corporation |
Nicotinamide derivative used as a p38 kinase inhibitor
|
WO2008072079A2
(en)
|
2006-12-13 |
2008-06-19 |
Pfizer Products Inc. |
Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide
|
AR064307A1
(es)
|
2006-12-13 |
2009-03-25 |
Gilead Sciences Inc |
Monofosfatos utiles para el tratamiento de la inflamacion pulmonar y broncoconstriccion, formulaciones aerosolicas que los contienen, y metodo de preparacion.
|
JP2010513370A
(ja)
|
2006-12-19 |
2010-04-30 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピラゾロ[3,4−d]ピリミジンp38MAPキナーゼインヒビター
|
US20100004293A1
(en)
|
2006-12-20 |
2010-01-07 |
Bristol-Myers Squibb Company |
Crystalline forms of aryl-substituted pyrazole-amide compounds
|
WO2008089034A2
(en)
|
2007-01-11 |
2008-07-24 |
Kemia, Inc. |
Cytokine inhibitors
|
US8063094B2
(en)
|
2007-02-08 |
2011-11-22 |
Boehringer Ingelheim International Gmbh |
Anti-cytokine heterocyclic compounds
|
ES2423929T3
(es)
|
2007-02-16 |
2013-09-25 |
Aska Pharmaceutical Co., Ltd. |
Composición farmacéutica que contiene suspensión basada en aceite de partículas finas
|
CA2689042A1
(en)
|
2007-02-16 |
2008-08-28 |
Merck & Co., Inc. |
Compositions and methods for potentiated activity of biologicaly active molecules
|
WO2008104473A2
(en)
|
2007-02-28 |
2008-09-04 |
F. Hoffmann-La Roche Ag |
Pyrazolopyriidine derivatives and their use as kinase inhibitors
|
ES2364727T3
(es)
|
2007-03-16 |
2011-09-13 |
Pfizer Limited |
Sal clorhidrato de 5-[3-(3-hidroxifenoxi)azetidin-1-il]-5-metil-2,2-difenilhexanamida.
|
EP2152706A1
(en)
|
2007-05-07 |
2010-02-17 |
Amgen Inc. |
Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
|
US7846944B2
(en)
|
2007-05-07 |
2010-12-07 |
Amgen Inc. |
Pyrazolo-pyridinone compounds and methods of use thereof
|
CA2692713A1
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Heterocyclic modulators of pkb
|
WO2009011871A2
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of pkb
|
US7943658B2
(en)
|
2007-07-23 |
2011-05-17 |
Bristol-Myers Squibb Company |
Indole indane amide compounds useful as CB2 agonists and method
|
US8202899B2
(en)
|
2007-07-25 |
2012-06-19 |
Array Biopharma Inc. |
Pyrazole urea derivatives used as kinase inhibitors
|
CA2699463A1
(en)
|
2007-09-14 |
2009-03-19 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
WO2009038784A1
(en)
|
2007-09-21 |
2009-03-26 |
Amgen Inc. |
Triazole fused heteroaryl compounds as p38 kinase inhibitors
|
ES2399945T3
(es)
|
2007-11-30 |
2013-04-04 |
Pfizer Limited |
Agonistas novedosos de los receptores de glucocorticoides
|
GB0724258D0
(en)
|
2007-12-12 |
2008-01-30 |
Glaxo Group Ltd |
Novel combinations
|
WO2009074518A1
(en)
|
2007-12-12 |
2009-06-18 |
Glaxo Group Limited |
Combinations of prolinamide p2x7 modulators with further therapeutic agents
|
WO2009078992A1
(en)
|
2007-12-17 |
2009-06-25 |
Amgen Inc. |
Linear tricyclic compounds as p38 kinase inhibitors
|
US20110166154A1
(en)
|
2008-01-25 |
2011-07-07 |
Bristol-Myers Squibb Company |
Identification of predictive markers of response to dasatinib in human colon cancer
|
US20110203586A1
(en)
|
2008-02-20 |
2011-08-25 |
Boehringer Ingelheim International Gmbh |
Powder Inhalers
|
US8367671B2
(en)
|
2008-03-21 |
2013-02-05 |
Amgen Inc. |
Pyrazolo[3.4-B]pyrazine compounds as p38 modulators and methods of use as anti-inflamatory agents
|
JP2009263234A
(ja)
|
2008-04-21 |
2009-11-12 |
Ranbaxy Lab Ltd |
ホスホジエステラーゼタイプiv阻害剤の組成物
|
AR072008A1
(es)
|
2008-06-13 |
2010-07-28 |
Merck & Co Inc |
Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
|
US8410128B2
(en)
|
2008-06-20 |
2013-04-02 |
Bristol-Myers Squibb Company |
Triazolopyridine compounds useful as kinase inhibitors
|
EP2300466B1
(en)
|
2008-06-20 |
2014-08-06 |
Bristol-Myers Squibb Company |
Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
|
WO2009158450A1
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, preparation and use thereof
|
WO2009158446A2
(en)
|
2008-06-25 |
2009-12-30 |
Bristol-Myers Squibb Company |
Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof
|
US8263623B2
(en)
|
2008-07-11 |
2012-09-11 |
Pfizer Inc. |
Triazol derivatives useful for the treatment of diseases
|
CA2727769A1
(en)
|
2008-07-15 |
2010-01-21 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
WO2010007561A1
(en)
|
2008-07-15 |
2010-01-21 |
Pfizer Limited |
Novel compounds active as muscarinic receptor antagonists
|
ES2387474T3
(es)
|
2008-08-29 |
2012-09-24 |
Amgen, Inc |
Compuestos de piridazino-piridinona para el tratamiento de enfermedades mediadas por proteína cinasa
|
US8420649B2
(en)
|
2008-08-29 |
2013-04-16 |
Amgen Inc. |
Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
|
WO2010038428A1
(ja)
|
2008-09-30 |
2010-04-08 |
武田薬品工業株式会社 |
タキサン系抗がん剤の置き換え薬
|
EP2206534A1
(de)
|
2008-10-09 |
2010-07-14 |
c-a-i-r biosciences GmbH |
Dibenzocycloheptanonderivate und pharmazeutische Mittel, welche diese Verbindungen enthalten
|
WO2010042646A1
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
|
WO2010042649A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
|
WO2010083246A1
(en)
|
2009-01-15 |
2010-07-22 |
Amgen Inc. |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
US20120129820A1
(en)
|
2009-02-09 |
2012-05-24 |
Boehringer Ingelheim International Gmbh |
New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
WO2010093889A2
(en)
|
2009-02-13 |
2010-08-19 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 2-(2, 4-difluorophenyl)-6-(1-(2,6-difluorophenyl)ureido)nicotinamide
|
EP2396302A2
(en)
|
2009-02-13 |
2011-12-21 |
Vertex Pharmceuticals Incorporated |
Processes for producing phenyl-6-(1-(phenyl)ureido)nicotinamides)
|
BRPI1005327A2
(pt)
|
2009-02-17 |
2019-09-24 |
Chiesi Farm Spa |
derivados de triazolopiridina como inibidores de p38 map quinase
|
GB0902648D0
(en)
|
2009-02-17 |
2009-04-01 |
Argenta Discovery Ltd |
Pharmaceutical compounds and compositions
|
US20120035177A1
(en)
|
2009-04-16 |
2012-02-09 |
Bristol-Myers Squibb Company |
Tablet formulation for p38 inhibitor and method
|
WO2010129208A1
(en)
|
2009-05-05 |
2010-11-11 |
Merck Sharp & Dohme Corp. |
P38 kinase inhibiting agents
|
US20120157500A1
(en)
|
2009-08-24 |
2012-06-21 |
Weikang Tao |
Jak inhibition blocks rna interference associated toxicities
|
MX2012004638A
(es)
|
2009-10-22 |
2012-07-04 |
Genentech Inc |
Modulacion de degeneracion de axones.
|
WO2011063076A1
(en)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Methods of treating hepatitis c virus with oxoacetamide compounds
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
CN104320971A
(zh)
|
2010-03-24 |
2015-01-28 |
安哥洛华治疗公司 |
用于预防和治疗创伤的组合物和方法
|
PL2552199T3
(pl)
|
2010-03-26 |
2015-11-30 |
Onconova Therapeutics Inc |
Ulepszony trwały wodny preparat (E)-4-karboksystyrylo-4chlorobenzylosulfonu
|
GB201009731D0
(en)
|
2010-06-10 |
2010-07-21 |
Pulmagen Therapeutics Inflamma |
Kinase inhibitors
|
ES2792799T3
(es)
|
2010-06-28 |
2020-11-12 |
Merck Patent Gmbh |
[1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer
|
BR112012033658A2
(pt)
|
2010-07-05 |
2016-11-29 |
Merck Patent Gmbh |
derivados bipiridílicos úteis para o tratamento de doenças induzidas por quinases
|
WO2012031057A1
(en)
|
2010-09-01 |
2012-03-08 |
Bristol-Myers Squibb Company |
Bms- 582949 for the treatment of resistant rheumatic disease
|
CA2818010A1
(en)
|
2010-11-29 |
2012-06-07 |
Genentech, Inc. |
Methods for detecting neurodegenerative diseases or disorders
|
TWI410425B
(zh)
|
2010-12-03 |
2013-10-01 |
Lilly Co Eli |
唑并[5,4-b]吡啶-5-基化合物
|
US9051318B2
(en)
|
2011-03-09 |
2015-06-09 |
Merck Patent Gmbh |
Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
|
CN103842362B
(zh)
|
2011-05-09 |
2017-05-24 |
爱普制药有限责任公司 |
用于治疗阿尔茨海默氏病的组合物和方法
|
ME02297B
(me)
|
2011-06-10 |
2016-02-20 |
Chiesi Farm Spa |
Jedinjenja koja imaju aktivnost antagonista muskarinskih receptora i agonist beta2 adrenergičnog receptora
|
EP3111937B1
(en)
|
2011-07-08 |
2020-06-17 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Medicament for treatment of liver cancer
|
JP6055481B2
(ja)
|
2011-11-11 |
2016-12-27 |
イーライ リリー アンド カンパニー |
卵巣癌のための併用療法
|
WO2013086002A1
(en)
|
2011-12-05 |
2013-06-13 |
Cellworks Research India Private Limited |
Compositions, process of preparation of said compositions and method of treating cancer
|
CN105968110B
(zh)
|
2011-12-09 |
2018-04-27 |
奇斯药制品公司 |
激酶抑制剂
|
CA2860479A1
(en)
|
2011-12-09 |
2013-06-13 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
BR112014013178A2
(pt)
|
2011-12-09 |
2017-06-13 |
Chiesi Farm Spa |
composto, composição farmacêutica e uso de um composto
|
KR102204989B1
(ko)
|
2012-01-12 |
2021-01-20 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
JP6177809B2
(ja)
|
2012-03-01 |
2017-08-09 |
アレイ バイオファーマ、インコーポレイテッド |
1−(3−tert−ブチル−1−p−トリル−1H−ピラゾール−5−イル)−3−(5−フルオロ−2−(1−(2−ヒドロキシエチル)−インダゾール−5−イルオキシ)ベンジル)ウレア塩酸塩の結晶形態
|
NZ628392A
(en)
|
2012-03-20 |
2016-06-24 |
Mereo Biopharma 1 Ltd |
Use of a pyrazole derivative in the treatment of acute exacerbations of chronic obstructive pulmonary disease
|
MX2014013407A
(es)
|
2012-05-22 |
2014-11-26 |
Hoffmann La Roche |
Dipiridilaminas sustituidas y uso de las mismas.
|
JP2015522612A
(ja)
*
|
2012-07-17 |
2015-08-06 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC |
急性冠症候群の治療におけるニコチンアミド誘導体
|
GB201214750D0
(en)
|
2012-08-17 |
2012-10-03 |
Respivert Ltd |
Compounds
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
GB201215357D0
(en)
|
2012-08-29 |
2012-10-10 |
Respivert Ltd |
Compounds
|
US20150210722A1
(en)
|
2012-08-29 |
2015-07-30 |
Respivert Limited |
Kinase inhibitors
|
EP2890695A2
(en)
|
2012-08-29 |
2015-07-08 |
Respivert Limited |
Kinase inhibitors
|
US9155747B2
(en)
|
2012-09-13 |
2015-10-13 |
Chiesi Farmaceutici S.P.A. |
Isoxazolidine derivatives
|
WO2014076484A1
(en)
|
2012-11-16 |
2014-05-22 |
Respivert Limited |
Kinase inhibitors
|
MX2015006457A
(es)
|
2012-11-30 |
2015-08-14 |
Hoffmann La Roche |
Inhibidores de la tirosina cinasa de bruton.
|
US9370527B2
(en)
|
2012-12-28 |
2016-06-21 |
The Regents Of The University Of Michigan |
Amelioration of intestinal fibrosis and treatment of Crohn's disease
|
US9790206B2
(en)
|
2013-02-27 |
2017-10-17 |
Array Biopharma Inc. |
Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof
|
WO2014140582A1
(en)
|
2013-03-14 |
2014-09-18 |
Respivert Limited |
Kinase inhibitors
|
GB201305714D0
(en)
|
2013-03-28 |
2013-05-15 |
Ucl Business Plc |
Method
|
EP2981535B8
(en)
|
2013-04-02 |
2021-03-10 |
Oxular Acquisitions Limited |
Urea derivatives useful as kinase inhibitors
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
CN105308046A
(zh)
|
2013-06-06 |
2016-02-03 |
奇斯药制品公司 |
激酶抑制剂
|
US9573949B2
(en)
|
2013-06-06 |
2017-02-21 |
Chiesi Farmaceutici S.P.A. |
Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
|
BR112015029970A2
(pt)
|
2013-06-06 |
2017-07-25 |
Chiesi Farm Spa |
inibidores de cinase
|
AU2014289296A1
(en)
*
|
2013-07-10 |
2016-02-04 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for use in treating glomerular disease
|
WO2015006752A1
(en)
|
2013-07-12 |
2015-01-15 |
The Regents Of The University Of California |
Combination therapies for malaria
|
US9814728B2
(en)
*
|
2013-09-20 |
2017-11-14 |
Saint Louis University |
Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi)
|
US10813920B2
(en)
*
|
2013-11-14 |
2020-10-27 |
The Doshisha |
Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
CN106029651A
(zh)
|
2013-12-20 |
2016-10-12 |
瑞斯比维特有限公司 |
用作激酶抑制剂的脲衍生物
|
EA034927B1
(ru)
|
2014-02-14 |
2020-04-07 |
Респайверт Лимитед |
Ароматические гетероциклические соединения как противовоспалительные соединения
|
MA39225A1
(fr)
|
2014-02-19 |
2017-04-28 |
H Lundbeck As |
2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tétrahydropyridines utilisées en tant qu'inhibiteurs de bace1 dans le traitement de la maladie d'alzheimer
|
CN107073121A
(zh)
|
2014-06-13 |
2017-08-18 |
基因泰克公司 |
治疗及预防癌症药物抗性的方法
|
JP2017517558A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
癌薬剤耐性の治療方法及び防止方法
|
CN113018300A
(zh)
|
2014-07-09 |
2021-06-25 |
爱普制药有限责任公司 |
用于治疗神经病症的方法
|
WO2016051186A1
(en)
|
2014-10-01 |
2016-04-07 |
Respivert Limited |
N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors
|
MA40774A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
|
WO2016049677A1
(en)
|
2014-10-03 |
2016-04-07 |
The Walter And Eliza Hall Institute Of Medical Research |
Method of treating cancer
|
WO2016066687A1
(en)
*
|
2014-10-30 |
2016-05-06 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Losmapimod for treating copd
|
WO2016114655A1
(en)
*
|
2015-01-12 |
2016-07-21 |
Ry Pharma B.V. |
Treating neuromuscular or neurologic disease through reducing gabaergic and/or glycinergic inhibitory neurotransmitter overstimulation
|
US10538763B2
(en)
*
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
ES2918975T3
(es)
*
|
2015-02-06 |
2022-07-21 |
Association Inst De Myologie |
Tratamiento de la distrofia facioescapulohumeral
|
TWI703138B
(zh)
|
2015-02-12 |
2020-09-01 |
義大利商吉斯藥品公司 |
具有蕈毒鹼受體拮抗劑及β2腎上腺素受體促效劑活性之化合物
|
EP3268373B1
(en)
|
2015-03-09 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Tricyclic dlk inhibitors and uses thereof
|
WO2016154329A2
(en)
*
|
2015-03-24 |
2016-09-29 |
The Trustees Of The University Of Pennsylvania |
P38 map kinase inhibitors for treating friedreich's ataxia
|
JP2016193870A
(ja)
|
2015-04-01 |
2016-11-17 |
国立大学法人広島大学 |
慢性骨髄性白血病治療剤
|
US9968604B2
(en)
|
2015-04-16 |
2018-05-15 |
Chiesi Farmaceutici S.P.A. |
Chromene derivatives as phoshoinositide 3-kinases inhibitors
|
WO2016186177A1
(ja)
*
|
2015-05-20 |
2016-11-24 |
大日本住友製薬株式会社 |
Wt1抗原ペプチドおよび免疫調節剤の併用
|
WO2016198698A2
(en)
|
2015-06-12 |
2016-12-15 |
Cnic Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii |
P38 inhibitors for the treatment and prophylaxis of liver cancer
|
CN108137586B
(zh)
|
2015-09-14 |
2021-04-13 |
辉瑞大药厂 |
作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
|
KR20180101322A
(ko)
|
2015-10-26 |
2018-09-12 |
이아이피 파마 엘엘씨 |
뇌졸중으로부터의 회복을 위한 방법 및 조성물
|
US9427439B1
(en)
|
2015-10-26 |
2016-08-30 |
Eip Pharma, Llc |
Methods and compositions for recovery from stroke
|
EP3383867B1
(en)
|
2015-12-03 |
2021-04-14 |
Chiesi Farmaceutici S.p.A. |
Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
|
WO2017108736A1
(en)
|
2015-12-23 |
2017-06-29 |
Chiesi Farmaceutici S.P.A. |
N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
|
CA3008113A1
(en)
|
2015-12-24 |
2017-06-29 |
The Doshisha |
Drug for treating or preventing disorder caused by tgf-.beta. signals, and application thereof
|
CA3010101A1
(en)
|
2015-12-29 |
2017-07-06 |
Board Of Regents, The University Of Texas System |
Inhibition of p38 mapk for the treatment of cancer
|
JP2019507186A
(ja)
*
|
2016-02-01 |
2019-03-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
マウス衛星細胞の増殖のための小分子
|
EP3411375B1
(en)
|
2016-02-04 |
2020-08-05 |
Chiesi Farmaceutici S.p.A. |
Pyrazole derivatives as phosphoinositide 3-kinases inhibitors
|
CN115105601A
(zh)
|
2016-06-08 |
2022-09-27 |
投资支持有限公司 |
用于治疗癌症的药物组合
|
GB201611712D0
(en)
|
2016-07-02 |
2016-08-17 |
Hvivo Services Ltd |
Methods and compounds for the treatment or prevention of severe or persistent influenza
|
US11123349B2
(en)
|
2017-02-15 |
2021-09-21 |
The University Of Melbourne |
Method of treatment
|
US10342786B2
(en)
|
2017-10-05 |
2019-07-09 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
|
CA3128468A1
(en)
*
|
2017-10-05 |
2019-04-11 |
Fulcrum Therapeutics, Inc. |
P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
|
WO2019103926A1
(en)
|
2017-11-21 |
2019-05-31 |
Saint Louis University |
P38 inhibitors for the treatment of fshd
|
MX2021005843A
(es)
|
2018-11-20 |
2021-10-01 |
Fulcrum Therapeutics Inc |
Composiciones y métodos para aumentar la hemoglobina fetal y tratar la anemia de células falciformes.
|
US20220079951A1
(en)
*
|
2018-12-20 |
2022-03-17 |
Saint Louis University |
Bet inhibitors for modulating dux4 expression in fshd
|
TW202102495A
(zh)
|
2019-03-15 |
2021-01-16 |
美商弗爾康醫療公司 |
Eed及prc2調節劑之巨環唑并吡啶衍生物
|
JP2023541404A
(ja)
*
|
2020-09-11 |
2023-10-02 |
アローヘッド ファーマシューティカルズ インコーポレイテッド |
DUX4の発現を阻害するためのRNAi剤、その組成物、及び使用方法
|